CHICAGO, ILLINOIS --- JUNE 19, 2017 --- Firma Clinical Research, an ISO quality management-certified clinical research organization (CRO), announced its launch and official unveiling at the Drug Information Association (DIA) 2017 Conference in Chicago, Illinois, June 18-22, 2017. The new company combines the expertise of Pharma Start and H20 Clinical, two clinical service organizations previously working in close collaboration, following an investment with management by Thompson Street Capital Partners, a St. Louis-based private equity firm. Built on decades of clinical development leadership and expertise, Firma Clinical supports the drug development efforts of pharmaceutical and biotech companies through advanced in-home patient visits, data management & biostatistics, medical writing, regulatory consulting, clinical pharmacology, and clinical operations. The executive team at Firma Clinical is led by:
The newly-formed Board of Directors consists of Chairman, Stephen Sullivan, Founder, CRO Advisors, LLC, Matt Scherrer, Managing Director, Thompson Street Capital Partners, Eugenia Henry, Chrissy Fleming, and Earl Henry. “We’re passionate about providing our clients with the highest-quality experience for every project we take on,” said Fleming. “We’re excited to apply that passion, knowledge, and flexibility by working side-by-side with our clients as partners to advance medicine and treatments to improve human lives.” “Our new brand and singular organization structure formalizes our unique approach to solving challenges and serving our clients in clinical development. This corporate transformation is the reflection of the collaboration and support that inspires our team to continue advancing the development of work with our clients on all of our projects,” Eugenia Henry added. Firma will be exhibiting at DIA in booth #1548. Contact us to schedule a time to meet with a team member and learn how our support can facilitate your team in making informed decisions that lead to better development outcomes. For additional information, please call 888.330.1726 or contact us at info@firmaclinical.com.
About Firma Clinical Research
An ISO 9001:2015 quality-certified organization, Firma Clinical provides focused CRO services enabling pharmaceutical and biotech clients to plan for and advance research in the drug development landscape. This support enables clients to make informed decisions that lead to better outcomes. Firma is dedicated to a collaborative approach that accelerates the development of safe and effective treatments for the pharmaceutical, biotechnology, and medical device industries. The company offers a wide array of tailored processes and services across all phases of clinical development, strategically focusing on flexible solutions, transparent communication, and on-time deliverables. For more information, please visit www.firmaclinical.com.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.